2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994
2003 Publications Abstracts
DOMAIN SPECIFICITY OF AUTOANTIBODIES TO BETA2-GLYCOPROTEIN I IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME ENROLLED IN A PHASE 1/2 TRIAL WITH LJP 1082 Matthew D. Linnik, et al. Presented at the 67th Annual Meeting of the American College of Rheumatology Orlando, FL October 23-28, 2003
SLE PATIENTS WITH SUSTAINED REDUCTIONS IN ANTI-DSDNA ANTIBODIES HAVE A REDUCED RISK OF RENAL FLARE AND MAJOR SLE FLARE Matthew D Linnik, et al. Presented at the 67th Annual Meeting of the American College of Rheumatology Orlando, FL October 23-28, 2003
RESULTS OF A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PHASE 1/2 CLINICAL TRIAL (RCT) TO ASSESS THE SAFETY AND TOLERABILITY OF LJP 1082 IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME Arash Horizon, et al. Presented at the 67th Annual Meeting of the American College of Rheumatology Orlando, FL October 23-28, 2003
SMALL MOLECULE INHIBITORS OF SSAO AS THERAPEUTICS FOR INFLAMMATORY AND AUTOIMMUNE DISORDERS Luisa Salter-Cid, et al Presented at Inflammatory Processes in Drug Discovery Philadelphia, PA September 22-23, 2003
IN VIVO CHARACTERIZATION OF BIOCONJUGATE B CELL TOLERAGENS WITH SPECIFICITY FOR AUTOANTIBODIES IN ANTIPHOSPHOLIPID SYNDROME Cockerill KA, et al. Published in International Immunopharmacology, 2003 Volume 3, Issue 12: pp 1667-1675
MULTIVALENT POLY(ETHYLENE GLYCOL)-CONTAINING CONJUGATES FOR IN VIVO ANTIBODY SUPPRESSION Dave Jones, et al Published in Bioconjugate Chemistry, 2003 Volume 14, Issue 6: 1067-1076